argenx NV ADR (ARGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, argenx NV ADR (ARGX) has a cash flow conversion efficiency ratio of 0.089x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($751.74 Million) by net assets ($8.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is argenx NV ADR worth for the company's overall valuation and market capitalisation.
argenx NV ADR - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how argenx NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
argenx NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of argenx NV ADR ranked by their cash flow conversion efficiency. Explore ARGX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ING Groep N.V
MX:INGN
|
N/A |
|
Hess Corporation
NYSE:HES
|
0.113x |
|
Bank Central Asia Tbk
JK:BBCA
|
0.022x |
|
Nu Holdings Ltd.
F:M1Z
|
0.073x |
|
Ambev SA ADR
NYSE:ABEV
|
0.035x |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
N/A |
|
Carrier Global Corp
NYSE:CARR
|
0.069x |
|
Ambev S.A
MX:ABEVN
|
0.075x |
Annual Cash Flow Conversion Efficiency for argenx NV ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of argenx NV ADR from 2011 to 2025. View argenx NV ADR share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.32 Billion | $850.49 Million | 0.116x | +871.70% |
| 2024-12-31 | $5.50 Billion | $-82.75 Million | -0.015x | +85.33% |
| 2023-12-31 | $4.10 Billion | $-420.33 Million | -0.103x | +66.55% |
| 2022-12-31 | $2.81 Billion | $-862.81 Million | -0.307x | -28.06% |
| 2021-12-31 | $2.53 Billion | $-606.81 Million | -0.239x | -0.60% |
| 2020-12-31 | $1.67 Billion | $-398.46 Million | -0.238x | -285.30% |
| 2019-12-31 | $1.18 Billion | $151.63 Million | 0.128x | +228.46% |
| 2018-12-31 | $615.87 Million | $-61.59 Million | -0.100x | +5.62% |
| 2017-12-31 | $413.81 Million | $-43.84 Million | -0.106x | -163.35% |
| 2016-12-31 | $66.65 Million | $11.15 Million | 0.167x | +144.93% |
| 2015-12-31 | $40.82 Million | $-15.19 Million | -0.372x | -192.85% |
| 2014-12-31 | $50.08 Million | $-6.37 Million | -0.127x | +58.24% |
| 2013-12-31 | $29.97 Million | $-9.12 Million | -0.304x | +54.29% |
| 2012-12-31 | $16.65 Million | $-11.09 Million | -0.666x | -366.23% |
| 2011-12-31 | $27.90 Million | $-3.98 Million | -0.143x | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more